Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.
The overall survival data were immature at the primary analysis of the study.
Endocrine therapy in combination with CDK4/6 inhibitors improves patients’ outcomes, but many still become treatment resistant.
The antibody-drug conjugate shows efficacy in reducing disease progression risk and increasing progression-free survival in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer.
Tucatinib is an oral HER2-targeting tyrosine kinase inhibitor that was approved by the FDA in 2020.
Rates of invasive breast cancer or death were 50% lower with adjuvant trastuzumab emtansine compared with trastuzumab alone.
Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.
These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.
The FDA is modernizing its approach to drug development and optimization.
A panel of experts discuss treatment of HR+, HER2– breast cancer with therapies such as ribociclib, alpelisib, everolimus, and elacestrant.
KN026 is a humanized bispecific antibody that targets and binds to HER2 proteins on the surface of cancer cells.
Palbociclib is an oral CDK4/6 inhibitor that was approved by the FDA in 2017.
Compared with chemotherapy, Dato-DXd demonstrates favorable median progression-free survival and overall survival in a phase 3 clinical trial.
The approach favors administration of frequent low-dose chemotherapy to reduce toxicities and optimize outcomes.
A new indication for the antibody-drug conjugate expands the future clinical potential of the treatment in patients with the rare breast cancer.
Palbociclib demonstrates safety and efficacy in combination with anti-HER2 and endocrine therapies.
Patients with hormone receptor–positive and human epidermal growth factor receptor 2 breast cancer are particularly at risk.
Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.
Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.
Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.
Trastuzumab deruxtecan and trastuzumab emtansine address key challenges such as recurrence and metastases in HER2+ early breast cancer treatment.
Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.
Experts discuss advancements in hormone receptor–positive/HER2-negative breast cancer treatment while addressing safety, diversity, and fertility challenges.
The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.
Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.
